Contraceptive Use and the Risk of Ovarian Cancer Among Women With a BRCA1 or BRCA2 Mutation
Women with a BRCA1 and BRCA2 mutation have a higher lifetime risk of developing ovarian cancer.
The Women’s Cancer Research Foundation (WCRF) annually publishes and funds numerous clinical studies on breast and gynecologic (ovarian, endometrial, and cervical) cancers. The WCRF’s oncology experts work tirelessly with the belief that each new clinical study has the potential to fundamentally improve the outcomes of patients diagnosed with breast and gynecologic cancers.